Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.62 |
| ▸ | DAO | P14920 | 1/20 | 0.62 |
| ▸ | ALPL | P05186 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085941 | 0.82 | HCAR2 (0.55) | HCAR2DAOALPLLMNAGAA | |
| SCHEMBL13299045 | 0.79 | HCAR2 (0.51) | HCAR2DAOALPLLMNAGAA | |
| SCHEMBL28875184 | 0.79 | HCAR2 (0.72) | HCAR2DAOALPLLMNAGAA | |
| SCHEMBL20525093 | 0.78 | PKM (0.38) | HCAR2DAOALPLLMNARAB9A | |
| SCHEMBL220072 | 0.77 | — | — | |
| SCHEMBL2629428 | 0.77 | — | — | |
| SCHEMBL16939218 | 0.76 | SMN1; SMN2 (0.41) | HCAR2DAOALPLGAARAB9A | |
| SCHEMBL16940977 | 0.76 | HCAR3 (0.66) | HCAR2LMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3760634 | 0.75 | — | — | |
| SCHEMBL4420054 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | claimed |
| US-20230159514-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-3099668-B1 | 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-108473495-B | Purinones as ubiquitin-specific protease 1 inhibitors | 福马治疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20210130343-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| US-10906896-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200046699-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20200031819-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10316031-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190119266-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190055234-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2018081251-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180057488-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-9828370-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2016172528-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311816-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| WO-2015116760-A1 | 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015116786-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316031-B2 | Compositions and methods for inhibiting kinases | MAP3K1, PACSIN2, MAP3K3 | HCAR2 4221/4885DAO 3336/4885ALPL 3490/4885 |
| US-20190119266-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | HCAR2 4221/4885DAO 3336/4885ALPL 3490/4885 |
| US-20190055234-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | HCAR2 4221/4885DAO 3336/4885ALPL 3490/4885 |
| US-20180057488-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | HCAR2 4221/4885DAO 3336/4885ALPL 3490/4885 |
| US-20200031819-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | HCAR2 4221/4885DAO 3336/4885ALPL 3490/4885 |
| US-20160311816-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | HCAR2 4221/4885DAO 3336/4885ALPL 3490/4885 |
| US-10906896-B2 | Compositions and methods for inhibiting kinases | MAP3K1, PACSIN2, MAP3K3 | HCAR2 4221/4885DAO 3336/4885ALPL 3490/4885 |
| US-20210130343-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | HCAR2 4221/4885DAO 3336/4885ALPL 3490/4885 |
| US-20230159514-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | HCAR2 4221/4885DAO 3336/4885ALPL 3490/4885 |
| US-20200046699-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | ABL1, FYN, PTK2 | HCAR2 4356/4885DAO 1382/4885ALPL 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.